Daniel L. Sparks
Ph.D., (ibid), B.Sc., (British Columbia)
Associate Professor, Department of Pathology and Laboratory Medicine, Faculty of Medicine
Associate Professor, Department of Biochemistry, Microbiology and Immunology
Research Scientist, University of Ottawa Heart Institute
Telephone: (613) 761-4822
Fax: (613) 761-5102
Areas of Clinical Expertise
- Cardiovascular and lipid therapeutics
- Drug development through Phase 1 and 2 clinical trials
Areas of Clinical Expertise
- Specialist Diploma in Sport Medicine (Liège, Belgium)
- University Diploma in Sport and Nutrition (Paris, France)
Areas of Laboratory Medicine Expertise
- Analytical chemistry
- Microscopy and pathohistology
- Animal pathophysiology
Dr. Sparks is a cardiovascular research scientist and operates a research laboratory at the University of Ottawa Heart Institute. The research in the laboratory of Dr. Sparks is focused to elucidate how the metabolism of lipid in the body is regulated and linked to the development of inflammatory disorders. Dr. Sparks founded a biopharmaceutical company to develop novel biotherapeutics for the treatment and prevention of hyperlipidemia and inflammatory diseases.
Cardiovascular Therapeutics: Plant derived phospholipids are rich in the omega-6 fatty acid, linoleic acid, and have therapeutic value to treat hyperlipidemia and inflammatory diseases of the liver and vasculature (Pandey, COID 2008).
Cholesterol Metabolism: Cholesterol accumulation in the blood stream is affected by enzymes that regulate the esterifcation and transport of cholesterol into the vascular storage pool. Cholesterol storage and excretion are controlled by lipoprotein charge. Lipoprotein electrostatic properties regulate interfacial enzyme activity and control the uptake and excretion of cholesterol by the liver (Sparks, CPL 2008).
Triglyceride metabolism: Patients with low plasma HDL-cholesterol levels often have elevated triglycerides. The inverse relationship between plasma HDL and triglyceride levels may be partly due to the ability of HDL to regulate triglyceride metabolism. Studies show that factors that stimulate HDL production affect plasma triglycerides levels by stimulating lipase secretion and triglyceride hydrolysis (Chatterjee, Biochemistry 2009).
HDL and Inflammation: Plasma HDL-cholesterol levels are low in patients with inflammatory disease. HDL levels are associated with the severity of inflammation in the body. Studies show that factors that increase HDL production impact inflammatory disease by directly blocking cellular inflammatory pathways (Pandey, Neuroscience 2009).
Pandey N.R., Sultan K., Twomey E., and Sparks D.L. (2009) “Phospholipids block NF-kB and tau phosphorylation and inhibit amyloid-b secretion in human neuroblastoma cells.” Neuroscience 164:1744-1753.
Pandey N.R., Renwick J., Rabaa S., Misquith A., Twomey E., and Sparks D.L. (2009) “A induction in hepatic HDL secretion associated with reduced ATPase expression.” The American Journal of Pathology 175:1777-1787
Young, E.K., Chatterjee, C., and Sparks, D.L. (2009) “HDL-apoE content regulates the displacement of hepatic lipase from cell surface proteoglycans.” The American Journal of Pathology 175:448-457
Chatterjee C., Young E., Pussegoda K.A., Twomey E.E., Pandey N.R., and Sparks D.L. (2009) “Hepatic apoA-I secretion regulates the mobilization of cell-surface hepatic lipase.” Biochemistry 48:5994-6001
Hopewell S.J., Pandey N.R., Misquith A., Twomey E., and Sparks D.L. (2008) “Phosphatidylinositol acts through mitogen-activated protein kinase pathways to stimulate hepatic apoA-I secretion.” Metabolism 57:1677-1684
Rouhani N., Young E., Chatterjee C. and Sparks D.L. (2008) “HDL composition regulates displacement of cell-surface bound hepatic lipase.” Lipids 43:793-804
Sparks D.L., Chatterjee C., Young E., Renwick J. and Pandey N.R. (2008) “Lipoprotein charge and vascular lipid metabolism.” Chemistry and Physics of Lipids 154:1-6
Pandey N.R., Renwick J., Misquith A., Sokoll K. and Sparks D.L. (2008) “Linoleic-acid enriched phospholipids act on PPARa to stimulate hepatic apoA-I synthesis and secretion.” Biochemistry 47:1579-87
Pandey N.R. and Sparks D.L. (2008) “Phospholipids as cardiovascular therapeutics.” Current Opinion in Investigational Drugs 9:281-285
Boucher J., Nguyen T. and Sparks D.L. (2007) “Lipoprotein electrostatic properties regulate hepatic lipase association and activity.” Biochemistry and Cell Biology 85:696-708